We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Galectin’s Fatty Liver Disease Drug Gets FDA Fast-Track Status
Galectin’s Fatty Liver Disease Drug Gets FDA Fast-Track Status
August 12, 2013
The FDA has granted Galectin Therapeutics’ fatty liver disease treatment GR-MD-O2 fast-track designation for the treatment of non-alcoholic steatohepatitis with hepatic fibrosis.